Neuvivo is a private, late-clinical stage biopharmaceutical company founded with the mission to create and deliver advanced treatments for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS). The company focuses on developing innovative therapeutics that address unmet medical needs in this challenging field. Neuvivo's flagship product, NP001, aims to regulate the innate immune system to improve respiratory function in ALS patients, positioning the company at the forefront of neurodegenerative disease treatment.
Notable affiliated individuals include Dr. James Kovach, who serves as Chief Medical Affairs Officer. Neuvivo has successfully raised $11 million in venture financing to advance its ALS treatment development. The company's research has led to groundbreaking studies linking the regulation of the innate immune system with respiratory function in ALS patients. Neuvivo's efforts have significantly impacted the biopharmaceutical landscape, offering new hope for patients suffering from debilitating neurodegenerative conditions.
